The effects of tualang honey on female reproductive organs, tibia bone and hormonal profile in ovariectomised rats - animal model for menopause by Zaid, Siti SM et al.
RESEARCH ARTICLE Open Access
The effects of tualang honey on female
reproductive organs, tibia bone and hormonal
profile in ovariectomised rats - animal model for
menopause
Siti SM Zaid
1†, Siti A Sulaiman
2†, Kuttulebbai NM Sirajudeen
3†, Nor H Othman
4*†
Abstract
Background: Honey is a highly nutritional natural product that has been widely used in folk medicine for a
number of therapeutic purposes. We evaluated whether Malaysian Tualang honey (AgroMas, Malaysia) was effective
in reducing menopausal syndrome in ovariectomised female rats; an animal model for menopause.
Methods: The rats were divided into two control groups and three test groups. The control groups were sham-
operated (SH) and ovariectomised (OVX) rats. The SH and OVX control rats were fed on 0.5 ml of distill water. The
rats in the test groups were fed with low dose 0.2 g/kg (THL), medium dose, 1.0 g/kg (THM) and high dose 2.0 g/
kg (THH) of Tualang honey in 0.5 ml of distill water. The administration was given by oral gavage once daily for
2 weeks. The reproductive organs (uterus and vagina), tibia bone and aorta were taken for histopathological
examination while serum for hormonal assays.
Results: Administration of Tualang honey for 2 weeks to ovariectomised rats significantly increased the weight of
the uterus and the thickness of vaginal epithelium, restored the morphology of the tibia bones and reduced the
body weight compared to rats in the ovariectomised group. The levels of estradiol and progesterone, in honey
treated groups were markedly lower than that in the OVX group. At low doses (0.2 g/kg; THL group) of Tualang
honey there was an increased in serum free testosterone levels compared to OVX group (P < 0.01). Progesterone
concentrations was significantly decreased in the OVX group as compared to SHAM group (P < 0.05).
Conclusions: Tualang honey was shown to have beneficial effects on menopausal (ovariectomised) rats by
preventing uterine atrophy, increased bone density and suppression of increased body weight. Honey could be an
alternative to HRT.
Background
Menopause is the time of life in women when menstrual
cycles and reproductive function permanently cease due
to loss of ovarian follicular activity [1,2]. Clinically, nat-
ural menopause can be diagnosed in women in their 40s
or 50s after 12 consecutive months of amenorrhea for
which no other obvious pathological or physiological
causes can be found [3,4]. It could also be induced by
surgery, chemotherapy or radiation [1,5].
There are various early and late complications of
menopausal period frequently referred as postmenopau-
sal syndrome such as vasomotor, psychogenic and sex-
ual problems. Later onset include increase incidence of
atherosclerosis, ischemic heart disease, stroke and osteo-
porosis [1,6,7]. In order to reduce these complications,
hormone replacement therapy (HRT) has been
prescribed extensively over the last 25 years [8,9]. Long-
term HRT use increases the risk of breast cancer, endo-
metrial cancer, thromboembolic events and vaginal
bleeding [10]. Such findings have resulted in a search
for alternatives to HRT.
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for its therapeutic effect. It has been reported to contain
about 200 substances such as mixture of sugars (fruc-
tose, glucose, maltose and sucrose), small amounts of
other constituents such as minerals, proteins, vitamins,
organic acids, flavonoids, phenolic acids, enzymes and
other phytochemicals [11]. Tualang honey is wild multi-
floral honey found in the Malaysian Rain Forest in
Malaysia. The honey bee specie is Apis Dorsata. Study
on postmenopausal women taking Tualang honey at
20 mg/day for 4 months were found to have similar
bone densitometry findings when compared with hor-
mone replacement therapy [12].
Royal jelly and propolis are other beehive products that
have been scientifically proven for their improvement of
menopausal syndrome [13,14]. Thus far, there are no
data on the benefits of honey on menopausal syndrome.
We conducted controlled experimentation using ovariec-
tomised rats as an animal model for menopausal syn-
drome to study the effect of Malaysian Tualang honey on
body weights, reproductive organs, tibia bone, aorta and
assayed the hormonal profiles of these rats.
Methods
The study was done on 3 months old, thirty-five virgin
female Sprague Dawley rats. The weights of the rats
were about 220-240 g and they were obtained from the
Laboratory Animal Research Unit (LARU), Health Cam-
pus, Universiti Sains Malaysia. After acclimatization for
aw e e k ,t h er a t sw e r ed i v i d e di n t o5g r o u p s( n=7 ) ;2
control and 3 test groups. The control rats either had
bilateral ovariectomy (OVX group) or sham-operated
(SHAM group) under diethyl ether anesthesia. The rats
in the test group had bilateral ovariectomy. The control
rats (SHAM and OVX) were given 0.5 ml of distilled
water. The test rats were given low dose; 0.2 g/kg (THL
group), medium dose; 1.0 g/kg (THM group) and high
dose; 2.0 g/kg (THH group) of Tualang honey topped
up to 0.5 ml of distill water. The administration was
started one day after surgery. The test and control rats
were oral gavaged with 0.5 ml honey or water at
approximately 9:00-10:00 am everyday for 2 weeks.
Throughout the treatment period all rats had daily vagi-
nal smear cytology to determine the estrous cycle
(reproductive cycle). Daily measurement of body weight
and the total food intake was recorded.
The Tualang honey used was supplied by Federal
Agricultural Marketing Authority (FAMA), Ministry of
Agriculture and Agro-Based Industry, Malaysia. The
water concentration of the honey was standardized by
FAMA at 18%.
After two weeks, the rats were sacrificed under excess
diethyl ether anesthesia. The blood samples were taken
from abdominal aorta and centrifuged at 2500 rpm for
15 min at 4°C to extract the serum for hormonal profile
analysis. The reproductive organs (uterine horn and
vagina) were carefully removed, cleaned, weighed and
fixed in 10% formalin. The heart and the attached aorta
were dissected and immersed in 10% formalin without
flushing out the blood. The right tibia was removed
from each rat and fixed with 70% ethanol. The men-
tioned organs were stained with Hematoxylin and Eosin
(H&E) and examined under light microscopy at 20×
magnification. The pathologist who evaluated the histol-
ogy of these organs (NHO - the corresponding author)
was blind to the treatment the rats received. The mean
vaginal epithelium and endometrial uterine thicknesses
was calculated based on measurements in six randomly
chosen areas of the sections using a computer-aided
program (Image-Pro Plus Version 5.0, USA).
Data analysis was done using Statistical Package for
Social Sciences (SPSS version 12.0.1) software. Statistical
analysis was performed using the Kruskall-Wallis test
for multiple comparisons, followed by Mann-Whitney
U-test to compare differences between two groups.
Results were expressed as median and interquartile
range (IR: the difference between the 75 and 25 percen-
tile). P values of less than 0.05 were considered statisti-
cally significant.
The protocol used in this study was approved by the
Animal Ethics Committee, Universiti Sains Malaysia
(approval # PPSG/07(A)/044).
Results
The relative weights of uterus, vagina and tibia bone of
control and test rats are shown in Table 1. The relative
weights of uterus showed marked decrease after ovar-
iectomy. On administration of Tualang honey at 0.2 g/
kg (THL group) and 1.0 g/kg (THM group) for 2 weeks
after ovariectomy, there was significant prevention (P <
0.05) of the loss of uterus relative weight compared to
non-honey treated rats (OVX group). Similarly, in
honey-treated rats, the weights of the vagina also
showed significant increased values when compared to
rats in OVX group. The thickness of the vaginal epithe-
lium and endometrium is also significantly different in
honey-treated rats compared to OVX group (Table 2).
Under light microscopy, we observed marked atrophy
of the rat uterus to about half its former size once the
rats are ovariectomised (OVX group). The size increased
to near normal in honey-treated rats (Figure 1). Likewise
the endometrial thickness showed atrophy in the OVX
group. After 2 weeks administration of Tualang honey
at all doses caused a complete reversal of the vaginal
atrophy (Figure 2). This effect was accompanied by mild
hyperplasia of vaginal epithelium. Cytoplasmic vacuoliza-
tion of vaginal epithelium was noted in rats on high dose
of 2.0 g/kg Tualang honey (THH group - Figure 2E).
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lium of the vagina of the honey-treated rats closely
resembled to that in SHAM rats.
The tibia bone weights was also heavier in honey-trea-
ted rats, however they are not statistically significant
(Table 1). Histological examination showed, Tualang
honey was able to restore the morphology of tibia bone
of ovariectomised rats to nearly its non-ovariectomised
state (Figure 3).
The effects of Tualang honey on serum estradiol, pro-
gesterone, free testosterone and FSH (follicle stimulating
hormone) are shown in Table 3. No significant changes
in serum concentrations of estradiol and FSH was noted
among all groups, however the values of these para-
meters in all honey treated groups was markedly lower
than that in the OVX group. At low doses (0.2 g/kg;
THL group) of Tualang honey there was a increased in
serum free testosterone in the ovariectomised rats (P <
0.01). Progesterone concentrations was significantly
decreased in the OVX group as compared to SHAM
group (P < 0.05) but no significant changes was
observed in Tualang honey treated rats. The values of
progesterone in the THL and THH groups were mark-
edly higher than that in the OVX group.
The changes in body and total food intake in all
groups are shown in Table 4. The body weights of ovar-
iectomised control rats were significantly greater than
the SHAM control group (P < 0.05). The ovariectomy-
induced increase in body weights were significantly
abolished after administration of Tualang honey at all
doses. The total food intakes were significantly higher in
OVX group as compared to SHAM and honey treated
groups. All animals in SHAM group demonstrated regu-
lar 4 to 5 days of estrous cycle. Control ovariectomised
and all honey treated rats showed metestrus and dies-
trus phase.
Histological examination of the aorta did not show
atheroma formation at the endothelial wall of control
and honey-treated rats.
Discussion
Our study showed administration of Tualang honey to
ovariectomised rats for 2 weeks significantly increased
the weights of the uterus, increased the thickness of
vaginal epithelium, restore the tibia bones and reduced
the body weights compared to control non-honey trea-
ted rats. It is interesting to note that significant change
in epithelial thickness, vagina and uterus weights were
seen in rats with lower doses of honey. The tibia bone
weights were also heavier in lower dose compared
to higher doses of honey, though not statistically
significant.
The animal model we used is akin to women in
menopause. Vaginal smear of all animals in SHAM con-
trol group in our study demonstrated regular 4 to 5
days of estrous cycle while control ovariectomised and
honey treated groups showed metestrus or diestrus
phases only. The result of these estrus cycle follow a
predictable cyclic pattern in a succinct 4-day time per-
iod. The 4-day estrus cycle is compromised of 1-day
phase and can be divided into diestrus 1, diestrus 2,
proestrus and estrus cycle [15]. In SHAM control group,
the existence of proestrus phase is analogous to the late
follicular/early luteal phases in fertile woman, which is
Table 1 Effects of Tualang honey on relative organ weight (mg/g body weight) after 2 weeks administration
SHAM OVX THL (0.2 g/kg) THM (1.0 g/kg) THH (2.0g/kg)
Vagina 60.51 (13.00) ** 48.26 (4.00) 54.98 (5.00)* 52.68 (3.00)* 55.49 (9.00)*
Uterus 178.38 (113.00) ** 62.35 (21.00) 83.49 (15.00)* 86.16 (20.00)* 69.46 (16.00)
Tibia 232.20 (32.00) 215.15 (16.00) 220.79 (12.00) 220.47 (11.00) 219.25 (27.00)
SHAM = Sham-operated control rats; OVX = ovariectomised non-honey treated control rats.
THL = Tualang Honey, low dose; THM = Tualang Honey, medium dose; THH = Tualang Honey, high dose.
All values are expressed as the median (IR).
a Kruskal - Wallis test.
*P < 0.05 and **P < 0.01 vs. OVX (Mann-Whitney U - test).
Table 2 Effects of Tualang honey on epithelial vaginal thickness and endometrial uterine thickness after 2 weeks
administration
SHAM OVX THL (0.2 g/kg) THM (1.0 g/kg) THH (2.0 g/kg)
Vaginal epithelium (μm) 49.72 (6.00)** 28.9 (7.00) 50.15 (19.00)** 43.41 (21.00)* 38.65 (9.00)**
Endometrium (μm) 436.05 (96.00)** 78.39 (168.00) 517.35 (125.00)* 489.09 (90.00) 506.81 (120.00)
SHAM = Sham-operated Control rats; OVX = overictomised non-honey treated Control rats.
THL = Tualang Honey, low dose; THM = Tualang Honey, medium dose; THH = Tualang Honey, high dose.
All values are expressed as the median (IR).
a Kruskal - Wallis test.
*P < 0.05 and **P < 0.01 vs. OVX (Mann-Whitney U - test).
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that immediately precedes ovulation (estrus). In ovariec-
tomised and honey treated rats we noted only metestrus
or diestrus phase indicating no ovulation had occurred
analogous to menopausal women. According to these
similarities with human, ovariecomised animals have
proven to be useful in studying various aspects of
hormone-induced changes [16].
Ovariectomy is a surgical procedure to induce meno-
pause in experimental animals. We showed in this study
the rats which were ovariectomised and not treated with
h o n e yh a dad r a m a t i cd e c r e a s ei nt h ew e i g h t so ft h e
reproductive organs particularly uterus and vagina com-
pared with rats which underwe n to n l ys h a mo p e r a t i o n .
The changes in weights seen in ovariectomised rats
were due to atrophy of endometrium and vaginal epithe-
lium resulting from lack of hormones secreted by the
ovaries. These imply that these tissues/organs are
affected in menopause. Menopause also reduces the
ability of epithelial cells to produce glycogen which
maintains low pH in vaginal fluid [15]. Changes in the
vaginal epithelium may lead to disturbances in vaginal
sensation noted after menopause.
On administration of Tualang honey at all doses, we
noted there was significant lack of atrophy of the vaginal
epithelium. The uterine endometrium maintained the
thickness in non-ovariectomised rats. We also noted
vacuolation of the vaginal epithelial cells implying
increase in mucopolysacharide (glycogen) content. If
inferred to human, such finding may be of benefit to
women who experience vaginal dryness after meno-
pause. The positive effects of Tualang honey is probably
due to its high nutritional contents, particularly flavo-
noids [17,18]. Flavonoids particularly kaempferol and
quercetin have been shown to have weak estrogenic
activity [16,17].
(A) SHAM control group (B) OVX control group               (C) THL group (0.2 g/kg)
(D) THM group (1.0 g/kg)          (E) THH group (2.0 g/kg)
Figure 1 Effects of Tualang honey on uterine morphology in
rats. OVX control group showed an atrophic uterus with cuboidal
endometrial epithelium, endometrium with cuboidal inactive cells
and stroma in less cellular. After 2 weeks administration of Tualang
honey at all doses has resulted in a partially reversal of uterine
atrophy. The increased thickness of endometrium in all treated
groups was due to an increased in the amount of collagen in the
stroma. All pictures are stained with H&E and examined under ×20
magnification: SHAM = Sham-operated control rats, OVX =
ovariectomised non-honey treated control rats, THL = Tualang
Honey, low dose, THM = Tualang Honey, medium dose, THH =
Tualang Honey, high dose.
(A) SHAM control group            (B) OVX control group             (C) THL group (0.2 g/kg)
(D) THM group (1.0 g/kg)         (E) THH group (2.0 g/kg)
Figure 2 Effects of Tualang honey on vagina morphology in
rats. OVX control group showed an atrophic vaginal epithelium
with composed of a few layers of flattened cells. After 2 weeks
administration of Tualang honey at all doses caused a complete
reversal of the vaginal atrophy. This effect was accompanied by
hyperplasia and hypertrophic of vaginal epithelium. The cytoplasmic
vacuolization was clearly present in THH group. All pictures are
stained with H&E and examined under ×20 magnification: SHAM =
Sham-operated control rats, OVX = ovariectomised non-honey
treated control rats, THL = Tualang Honey, low dose, THM =
Tualang Honey, medium dose, THH = Tualang Honey, high dose.
(A) SHAM control group            (B) OVX control group            (C) THL group (0.2 g/kg)
(D) THM group (1.0 g/kg)           (E) THH group (2.0 g/kg)
Figure 3 Effects of Tualang honey on trabecular thickness of
tibia bone. Histopathological examination (HPE) indicated that
Tualang honey is able to restore the trabecular thickness in tibia
bone of ovariectomised rats. All pictures are stained with H&E and
examined under ×20 magnification: SHAM = Sham-operated control
rats, OVX = ovariectomised non-honey treated control rats, THL =
Tualang Honey, low dose, THM = Tualang Honey, medium dose,
THH = Tualang Honey, high dose.
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the benefits of honey on reproductive organs however
the effects of other beehive products namely propolis
and royal jelly have been reported [13,14]. The composi-
tions of honey and beehive products are considerably
similar but qualitatively and quantitatively are dissimilar
depending on the regional plant ecology [18,19]. The
improvement of uterus and vagina atrophy is due to the
presence of biologically active estrogen-like molecules or
phytoestrogens in honey. Further, flavonoid, which is
present in honey are antioxidant compounds which
could retard biologically destructive chemical reactions
in living organisms through their ability to scavenge oxi-
dants and free radicals [20-22].
We observed the morphology of tibial bones of the
ovariectomised rats treated with Tualang were like those
of control non-ovariectomised rats. The positive effect
on bone density is probably due to honey containing
high flavonoids and gluconic acid. Previous investigators
claimed that gluconic acid which is the major organic
acid in honey and carbohydrate constituents could
enhance calcium absorption in the bone of rats [23,24].
Kaempferol (flavonoids compounds in honey) also has
osteogenic effect in ovariectomized rats [25].
Ovariectomy can induce an increase in body weight
and food intake [6,26]. Such findings were also observed
in the rats of our study. Previous studies have shown
that estrogen plays an important role in lipid metabo-
lism during premenopausal years [27]. Estrogen insuffi-
ciency during menopause is thought to be largely
responsible for an increase in adiposity, particularly
abdominal fat accumulation. When postmenopausal
women receive estrogen replacement therapy they do
not display the characteristic pattern of abdominal
weight gain associated with menopause. Changes in
androgenic profile nearer to that of man, have also been
suggested to be responsible for changes in body fat dis-
tribution during this period [1].
We observed body weight gain was significantly pre-
vented by Tualang honey administration at all doses.
This could be due to the nutrients found in honey; anti-
oxidants such as flavonoids and phenolic acids; enzymes
such as glucose oxidase, invertase, diastase (amylase),
catalase and acid phosphatase; organic acids such as glu-
conic acid, caffeic, ferulic, butyric, acetic, formic, lactic,
succinic, malic, citric, maleic, oxalic and pyroglutamic
and other nutriens such as vitamins and minerals [18].
Certain bioactive compounds in Tualang honey might
have prevented the gain in weight of ovariectomised
rats. We also observed the total food intake in ovariec-
tomised Tualang honey-treated rats were significantly
lower than ovariectomised non-honey treated rats.
Table 3 Effects of Tualang honey on serum estradiol, progesterone, free testosterone, follicle-stimulating hormone
(FSH) and luteinizing hormone (LH) after 2 weeks administration
SHAM OVX THL (0.2 g/kg) THM (1.0 g/kg) THH (2.0 g/kg)
Estradiol (pg/ml) 14.82 (13.00) 12.58 (9.00) 7.42 (6.00) 7.55 (8.00) 5.21 (0.01)
Progesterone (ng/mg) 14.59 (13.00)* 4.28 (4.00) 6.18 (14.00) 3.72 (4.00) 8.92 (11.00)
Free testosterone (pg/ml) 0.27 (0.01)** 0.03 (0.01) 0.05 (0.01)* 0.04 (0.01) 0.05 (0.10)
FSH (mlU/ml) 0.53 (0.01) 0.63 (0.01) 0.43 (1) 0.61 (0.01) 0.4 (0.01)
LH (mlU/ml) ND
a ND ND ND ND
SHAM = Sham-operated Control rats; OVX = overictomised non-honey treated Control rats.
THL = Tualang Honey, low dose; THM = Tualang Honey, medium dose; THH = Tualang Honey, high dose.
All values are expressed as the median (IR).
a Kruskal - Wallis test.
*P < 0.05 and **P < 0.01 vs. OVX (Mann-Whitney U - test).
aNot detectable (values below detection limit).
Table 4 Effects of Tualang honey on changes in body weight and total food intake after 2 weeks administration
SHAM OVX THL (0.2 g/kg) THM (1.0 g/kg) THH (2.0 g/kg)
Body weight on the first day of treatment (g) 229.0 226.0 221.0 229.0 229.0
Body weight at sacrifice (g) 234.0 261.0 252.0 259.0 258.0
Changes in body weight (%) 4.63 (3.00)** 17.60 (5.00) 15.38 (3.00)* 13.51 (7.00)* 10.73 (8.00)**
Total food intake (g) 211.0 (70.00) 269.0 (58.00) 196.0 (7.00) ** 218.0 (36.00)* 219.0 (18.00)*
SHAM = Sham-operated Control rats; OVX = overictomised non-honey treated Control rats.
THL = Tualang Honey, low dose; THM = Tualang Honey, medium dose; THH = Tualang Honey, high dose.
All values are expressed as the median (IR).
a Kruskal - Wallis test.
*P < 0.05 and **P < 0.01 vs. OVX (Mann-Whitney U - test).
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concentrated source of energy (313 calories per 100 g)
which help in reducing food intake.
The hormonal profiles in our honey treated rats show
mixed findings. At low doses (0.2 g/kg; THL group) of
Tualang honey there was an increased in serum free tes-
tosterone levels compared to OVX group (P < 0.01).
The level of estradiol reduces on treatment with honey
although not dose-related. The level of progestogens is
increased in low and high dose but not in medium dose
of honey. The reason for the mixed findings could be
due to our rats was only exposed to two weeks of
honey. It would be interesting to see the hormonal
changes if they are exposed for a longer period.
The rats in our study did not develop atheroma per-
haps also because of short study period. Previous studies
have reported that rats do not develop spontaneous
atherosclerosis except after 3 to 6 months on high fat
and cholesterol diet modifications [28,29].
Conclusions
Daily consumption of Tualang honey for 2 weeks in
female adult ovariectomised rats, a model for menopau-
sal symptoms, provided protective and beneficial effects.
Tualang honey was shown to prevent uterine atrophy,
vaginal epithelium atrophy, promote increased bone
density and suppress the increased of body weight seen
in menopausal state. Clinical trials are required to see if
these benefits could be translated to post menopausal
women.
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